Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702600 | 0.79 | ALDH1A1 (0.45) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL14191121 | 0.79 | ALDH1A1 (0.45) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL8751368 | 0.77 | ALDH1A1 (0.41) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL29314865 | 0.77 | TDP1 (0.44) | ALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL19493622 | 0.76 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL19493632 | 0.76 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL16770733 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL11455306 | 0.74 | ALDH1A1 (0.50) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL27363114 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL9963710 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345899-B1 | N-substituted amides as NK1 receptor antagonists | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| US-7064136-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | disclosed |
| US-20040058916-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| EP-1345899-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051807-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058916-A1 | Compounds | CYP11B2, CYP11B1, PCSK9 | ALDH1A1 816/4885LMNA 1082/4885HTT 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.